C
Charles M. Perou
Researcher at University of North Carolina at Chapel Hill
Publications - 645
Citations - 235604
Charles M. Perou is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 156, co-authored 573 publications receiving 202951 citations. Previous affiliations of Charles M. Perou include North Carolina Central University & University of Chicago.
Papers
More filters
Journal ArticleDOI
c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer
Radhika Nair,Daniel L. Roden,Wee Siang Teo,Wee Siang Teo,Andrea McFarland,Simon Junankar,Simon Junankar,S. Ye,S. Ye,Akira Nguyen,Jessica Yang,Iva Nikolic,Mun N. Hui,Adrienne Morey,Adrienne Morey,Jaynish S. Shah,Adam D. Pfefferle,Jerry Usary,C.I. Selinger,Laura A. Baker,Laura A. Baker,Nicola J. Armstrong,Mark J. Cowley,Matthew J. Naylor,Matthew J. Naylor,Matthew J. Naylor,Christopher J. Ormandy,Christopher J. Ormandy,Sunil R. Lakhani,Jason I. Herschkowitz,Charles M. Perou,Warren Kaplan,Warren Kaplan,Sandra A O'Toole,Alexander Swarbrick,Alexander Swarbrick +35 more
TL;DR: D markedly increased self-renewal and tumour-propagating capability of cells transformed with Her2 and c-Myc and in vitro models show that in HER2+ breast cancer patients receiving adjuvant chemotherapy (but not targeted anti-Her2 therapy), MYC amplification is associated with a poor outcome.
Journal ArticleDOI
In Vitro and In Vivo Analysis of B-Myb in Basal-Like Breast Cancer
Aaron R. Thorner,Katherine A. Hoadley,Joel S. Parker,Scott Winkel,Robert C. Millikan,Charles M. Perou +5 more
TL;DR: It is shown that B-Myb expression is a significant predictor of survival and pathological complete response to neoadjuvant chemotherapy in breast cancer patients, and that its dysregulation may contribute to increased sensitivity to a specific class of chemotherapeutic agents.
Journal ArticleDOI
MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion
Jessica Bockhorn,Kathy Yee,Ya Fang Chang,Aleix Prat,Dezheng Huo,Chika Nwachukwu,Rachel Dalton,Simo Huang,Kaitlin E. Swanson,Charles M. Perou,Olufunmilayo I. Olopade,Michael F. Clarke,Geoffrey L. Greene,Huiping Liu,Huiping Liu +14 more
TL;DR: It is shown that human breast tumor biomarker miR-30c regulates invasion by targeting the cytoskeleton network genes encoding twinfilin 1 (TWF1) and vimentin (VIM), which have been shown to regulate epithelial-to-mesenchymal transition.
Journal ArticleDOI
Erratum: The somatic genomic landscape of glioblastoma (Cell (2013) 155 (462-477))
Cameron Brennan,Roel G.W. Verhaak,Aaron McKenna,Benito Campos,Houtan Noushmehr,Sofie R. Salama,Siyuan Zheng,Debyani Chakravarty,J. Zachary Sanborn,Samuel H. Berman,Rameen Beroukhim,Brady Bernard,Chang-Jiun Wu,Giannicola Genovese,Ilya Shmulevich,Jill S. Barnholtz-Sloan,Lihua Zou,Rahulsimham Vegesna,Sachet A. Shukla,Giovanni Ciriello,W. K. Yung,Wei Zhang,Carrie Sougnez,Tom Mikkelsen,Kenneth Aldape,Darell D. Bigner,Erwin G. Van Meir,Michael D. Prados,Andrew E. Sloan,Keith L. Black,Jennifer M. Eschbacher,Gaetano Finocchiaro,William A. Friedman,David W. Andrews,Abhijit Guha,Mary Iacocca,Brian P. O'Neill,Greg Foltz,Jerome Myers,Daniel J. Weisenberger,Robert Penny,Raju Kucherlapati,Charles M. Perou,D. Neil Hayes,Richard A. Gibbs,Marco A. Marra,Gordon B. Mills,Eric S. Lander,Paul T. Spellman,Rick K. Wilson,Chris Sander,John N. Weinstein,Matthew Meyerson,Stacey Gabriel,Peter W. Laird,David Haussler,Gad Getz,Lynda Chin +57 more
Journal ArticleDOI
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
Miguel Martin,Aleix Prat,Álvaro Rodríguez-Lescure,Rosalía Caballero,Mark T. W. Ebbert,Blanca Munárriz,Manuel Ruiz-Borrego,Roy R. L. Bastien,C. Crespo,Carole Davis,César A. Rodríguez,J. M. López-Vega,V. Furio,Ana M. García,Maribel Casas,Matthew J. Ellis,Donald A. Berry,Brandelyn N. Pitcher,Lyndsay Harris,Amparo Ruiz,Eric P. Winer,Clifford A. Hudis,Inge J. Stijleman,David Tuck,Eva Carrasco,Charles M. Perou,Philip S. Bernard +26 more
TL;DR: The PAM50 proliferation score identifies a subset of patients with a low proliferation status that may derive a larger benefit from weekly paclitaxel and results were obtained in the CALGB data set, although the interaction test did not reach statistical significance.